These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
602 related articles for article (PubMed ID: 34996736)
1. Disentangling the signaling pathways of mTOR complexes, mTORC1 and mTORC2, as a therapeutic target in glioblastoma. Jhanwar-Uniyal M; Dominguez JF; Mohan AL; Tobias ME; Gandhi CD Adv Biol Regul; 2022 Jan; 83():100854. PubMed ID: 34996736 [TBL] [Abstract][Full Text] [Related]
2. Targeting the mTOR pathway using novel ATP‑competitive inhibitors, Torin1, Torin2 and XL388, in the treatment of glioblastoma. Amin AG; Jeong SW; Gillick JL; Sursal T; Murali R; Gandhi CD; Jhanwar-Uniyal M Int J Oncol; 2021 Oct; 59(4):. PubMed ID: 34523696 [TBL] [Abstract][Full Text] [Related]
3. Discrete signaling mechanisms of mTORC1 and mTORC2: Connected yet apart in cellular and molecular aspects. Jhanwar-Uniyal M; Amin AG; Cooper JB; Das K; Schmidt MH; Murali R Adv Biol Regul; 2017 May; 64():39-48. PubMed ID: 28189457 [TBL] [Abstract][Full Text] [Related]
4. Diverse signaling mechanisms of mTOR complexes: mTORC1 and mTORC2 in forming a formidable relationship. Jhanwar-Uniyal M; Wainwright JV; Mohan AL; Tobias ME; Murali R; Gandhi CD; Schmidt MH Adv Biol Regul; 2019 May; 72():51-62. PubMed ID: 31010692 [TBL] [Abstract][Full Text] [Related]
5. Distinct signaling mechanisms of mTORC1 and mTORC2 in glioblastoma multiforme: a tale of two complexes. Jhanwar-Uniyal M; Gillick JL; Neil J; Tobias M; Thwing ZE; Murali R Adv Biol Regul; 2015 Jan; 57():64-74. PubMed ID: 25442674 [TBL] [Abstract][Full Text] [Related]
6. Defining the role of mTOR pathway in the regulation of stem cells of glioblastoma. Jhanwar-Uniyal M; Gellerson O; Bree J; Das M; Kleinman G; Gandhi CD Adv Biol Regul; 2023 May; 88():100946. PubMed ID: 36658088 [TBL] [Abstract][Full Text] [Related]
7. Discrete Mechanistic Target of Rapamycin Signaling Pathways, Stem Cells, and Therapeutic Targets. Jhanwar-Uniyal M; Zeller SL; Spirollari E; Das M; Hanft SJ; Gandhi CD Cells; 2024 Feb; 13(5):. PubMed ID: 38474373 [TBL] [Abstract][Full Text] [Related]
8. RES-529: a PI3K/AKT/mTOR pathway inhibitor that dissociates the mTORC1 and mTORC2 complexes. Weinberg MA Anticancer Drugs; 2016 Jul; 27(6):475-87. PubMed ID: 26918392 [TBL] [Abstract][Full Text] [Related]
9. ATP-site binding inhibitor effectively targets mTORC1 and mTORC2 complexes in glioblastoma. Neil J; Shannon C; Mohan A; Laurent D; Murali R; Jhanwar-Uniyal M Int J Oncol; 2016 Mar; 48(3):1045-52. PubMed ID: 26719046 [TBL] [Abstract][Full Text] [Related]
10. Involvement of mTORC1 and mTORC2 in regulation of glioblastoma multiforme growth and motility. Gulati N; Karsy M; Albert L; Murali R; Jhanwar-Uniyal M Int J Oncol; 2009 Oct; 35(4):731-40. PubMed ID: 19724909 [TBL] [Abstract][Full Text] [Related]
11. RhoA modulates signaling through the mechanistic target of rapamycin complex 1 (mTORC1) in mammalian cells. Gordon BS; Kazi AA; Coleman CS; Dennis MD; Chau V; Jefferson LS; Kimball SR Cell Signal; 2014 Mar; 26(3):461-7. PubMed ID: 24316235 [TBL] [Abstract][Full Text] [Related]
12. Alkaline intracellular pH (pHi) increases PI3K activity to promote mTORC1 and mTORC2 signaling and function during growth factor limitation. Kazyken D; Lentz SI; Wadley M; Fingar DC J Biol Chem; 2023 Sep; 299(9):105097. PubMed ID: 37507012 [TBL] [Abstract][Full Text] [Related]
13. High prevalence of mTOR complex activity can be targeted using Torin2 in papillary thyroid carcinoma. Ahmed M; Hussain AR; Bavi P; Ahmed SO; Al Sobhi SS; Al-Dayel F; Uddin S; Al-Kuraya KS Carcinogenesis; 2014 Jul; 35(7):1564-72. PubMed ID: 24583924 [TBL] [Abstract][Full Text] [Related]
14. Preclinical characterization of OSI-027, a potent and selective inhibitor of mTORC1 and mTORC2: distinct from rapamycin. Bhagwat SV; Gokhale PC; Crew AP; Cooke A; Yao Y; Mantis C; Kahler J; Workman J; Bittner M; Dudkin L; Epstein DM; Gibson NW; Wild R; Arnold LD; Houghton PJ; Pachter JA Mol Cancer Ther; 2011 Aug; 10(8):1394-406. PubMed ID: 21673091 [TBL] [Abstract][Full Text] [Related]
15. Mechanistic Target of Rapamycin Complex 1 (mTORC1) and mTORC2 as Key Signaling Intermediates in Mesenchymal Cell Activation. Walker NM; Belloli EA; Stuckey L; Chan KM; Lin J; Lynch W; Chang A; Mazzoni SM; Fingar DC; Lama VN J Biol Chem; 2016 Mar; 291(12):6262-71. PubMed ID: 26755732 [TBL] [Abstract][Full Text] [Related]
16. Dual PI3K/mTOR Inhibitors Induce Rapid Overactivation of the MEK/ERK Pathway in Human Pancreatic Cancer Cells through Suppression of mTORC2. Soares HP; Ming M; Mellon M; Young SH; Han L; Sinnet-Smith J; Rozengurt E Mol Cancer Ther; 2015 Apr; 14(4):1014-23. PubMed ID: 25673820 [TBL] [Abstract][Full Text] [Related]
17. Differential effects of selective inhibitors targeting the PI3K/AKT/mTOR pathway in acute lymphoblastic leukemia. Badura S; Tesanovic T; Pfeifer H; Wystub S; Nijmeijer BA; Liebermann M; Falkenburg JH; Ruthardt M; Ottmann OG PLoS One; 2013; 8(11):e80070. PubMed ID: 24244612 [TBL] [Abstract][Full Text] [Related]
18. Dual Targeting of mTOR Activity with Torin2 Potentiates Anticancer Effects of Cisplatin in Epithelial Ovarian Cancer. Hussain AR; Al-Romaizan M; Ahmed M; Thangavel S; Al-Dayel F; Beg S; Uddin S; Siraj AK; Al-Kuraya KS Mol Med; 2015 May; 21(1):466-78. PubMed ID: 26023849 [TBL] [Abstract][Full Text] [Related]
19. FilGAP regulates tumor growth in Glioma through the regulation of mTORC1 and mTORC2. Tsutsumi K; Nohara A; Tanaka T; Murano M; Miyagaki Y; Ohta Y Sci Rep; 2023 Dec; 13(1):20956. PubMed ID: 38065968 [TBL] [Abstract][Full Text] [Related]
20. Autoregulation of the mechanistic target of rapamycin (mTOR) complex 2 integrity is controlled by an ATP-dependent mechanism. Chen CH; Kiyan V; Zhylkibayev AA; Kazyken D; Bulgakova O; Page KE; Bersimbaev RI; Spooner E; Sarbassov DD J Biol Chem; 2013 Sep; 288(38):27019-27030. PubMed ID: 23928304 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]